AMP has announced that it would maintain AXA North and AMP Flexible Super as part of its product and platform plans for the AXA/AMP merger.
AMP’s SignatureSuper would be its medium and large corporate superannuation product, while AMP Flexible Super would target small to medium businesses, the group added.
AMP would continue to invest in its two distinctive insurance offerings — AMP’s Flexible Lifetime Protection and AXA’s Elevate — to ensure they remained competitive, AMP stated. However, within the next two years the company would build a new retail insurance product range that would take the best attributes of the two current offerings.
AMP and AXA’s group risk products would remain, while the group aimed to enhance AMP’s group risk offer that supported AMP’s mastertrust superannuation product and invest in AXA’s stand-alone offer to capitalise on profitable growth opportunities.
Jim Chalmers has defended changes to the Future Fund’s mandate, referring to himself as a “big supporter” of the sovereign wealth fund, amid fierce opposition from the Coalition, which has pledged to reverse any changes if it wins next year’s election.
In a new review of the country’s largest fund, a research house says it’s well placed to deliver attractive returns despite challenges.
Chant West analysis suggests super could be well placed to deliver a double-digit result by the end of the calendar year.
Specific valuation decisions made by the $88 billion fund at the beginning of the pandemic were “not adequate for the deteriorating market conditions”, according to the prudential regulator.